



CIN: L24231KA1979PLC003563

February 11, 2015

The Manager – Listing  
**Bangalore Stock Exchange Ltd,**  
Stock Exchange Tower  
51, 1<sup>st</sup> Cross, J.C.Road  
Bangalore – 560027

The Manager – Listing  
**BSE Limited,**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sirs,

**Sub: Outcome of Board Meeting held on Wednesday, February 11, 2015**

**Ref: Scrip Code - Bgse: ASTRAZEN /BSE: 506820 / NSE: ASTRAZEN EQ**

At the Board Meeting of the Company held on Wednesday, February 11, 2015, the Board of Directors approved the Un-audited Financial Results of the Company for the third quarter ended December 31, 2014.

The said financial results together with the Limited Review Report issued by the Statutory Auditors are enclosed herewith.

Please take the same on record.

Thanking you,

Yours faithfully,  
for **AstraZeneca Pharma India Limited**

  
**Anantha Murthy N**  
**Legal Counsel and Company Secretary**

Enc: As above.

**CORPORATE & REGD OFFICE**  
**AstraZeneca Pharma India Ltd.**  
Block N1, 12<sup>th</sup> Floor  
Manyata Embassy Business Park  
Rachenahalli, Outer Ring Road  
Bangalore - 560045, INDIA

**TEL** : +91 80 67748000

**CIN** : L24231KA1979PLC003563

[www.astrazeneca.com/india](http://www.astrazeneca.com/india)

**FACTORY**  
**12th Mile on Bellary Road**  
Venkatala, Kattigenahalli Village  
Yelahanka  
Bangalore - 560 063  
INDIA

**TEL** : +91 80 67749000

**FAX** : +91 80 28462208  
+91 80 67749628



Segment wise revenue, results and capital employed

Sl.no	Particulars	3 months ended 31/12/2014 (Unaudited)	3 months ended 30/09/2014 (Unaudited)	3 months ended 31/12/2013 (Unaudited)	9 months ended 31/12/2014 (Unaudited)	9 months ended 31/12/2013 (Unaudited)	Previous year ended 31/03/2014 (Audited)
1	Segment revenue						
	(a) Healthcare	10,716.81	11,477.52	10,965.93	34,895.63	33,080.66	44,178.44
	(b) Others	103.41	(10.11)	929.65	(43.72)	2,901.22	3,218.66
	Total	10,820.22	11,467.41	11,895.58	34,851.91	35,981.88	47,397.10
	Net income from operations	10,820.22	11,467.41	11,895.58	34,851.91	35,981.88	47,397.10
2	Segment results						
	Profit/(loss) before tax and interest						
	(a) Healthcare	(1,460.93)	(2,982.81)	(147.37)	(6,392.97)	(1,144.73)	(3,113.81)
	(b) Others	9.75	26.13	141.28	45.79	622.40	804.06
	Total	(1,451.18)	(2,956.68)	(6.09)	(6,347.18)	(522.33)	(2,309.75)
	Add: Other income	110.28	160.68	157.88	450.26	779.21	920.84
	Add: Exceptional item	-	-	-	-	-	1,388.91
	Less: Interest	-	-	-	-	-	-
	Total profit/(loss) before tax	(1,340.90)	(2,796.00)	151.79	(5,896.92)	256.88	-
3	Capital employed						
	(a) Healthcare	8,165.92	6,454.30	7,079.94	8,165.92	7,079.94	7,829.14
	(b) Others	(266.00)	(407.52)	31.29	(266.00)	31.29	(559.23)
	(c) Unallocated	3,362.66	6,556.70	3,070.05	3,362.66	3,070.05	9,889.59
	Total	11,262.58	12,603.48	10,181.28	11,262.58	10,181.28	17,159.50

**Notes :**

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 The Company has an agreement with AstraZeneca AB, Sweden for global clinical trial studies to be undertaken in India. As per the terms of the agreement, the Company charges the cost incurred (External and Internal) on clinical trials plus a markup on the internal cost to AstraZeneca AB, Sweden. As at 31 December 2014, the Company has six studies ongoing in India for which the Company has incurred external cost aggregating to Rs 75.77 lakhs during the quarter ended 30 September 2014, Rs 104.31 lakhs during quarter ended 31 December 2014 and Rs 426.90 lakhs for nine months ended 31 December 2014. Certain reversal of provisional cost has resulted in a net reversal in the other revenue for the quarter ended 30 September 2014 and nine months ended 31 December 2014.
- 3 Exceptional item for the year ended 31 March 2014 represents receipt under subvention agreement credited to statement of profit and loss to the extent of losses incurred during the year ended 31 March 2014.